Skip to main content
. Author manuscript; available in PMC: 2020 Sep 25.
Published in final edited form as: Cancer Discov. 2012 Oct 25;3(1):68–81. doi: 10.1158/2159-8290.CD-12-0049

Figure 7.

Figure 7.

Chronic antitumor efficacy of the novel PARPi AZD2461. A, overall survival of mice receiving 100 days of olaparib (see also ref. 9) or AZD2461 treatment. After relapse of a tumor to a size of 100%, treatment was given for another 100 days. Individual tumor responses are shown in Supplementary Fig. S10AS10C. B, relapse-free survival of mice with a KB1P tumor that received AZD2461 for 28 consecutive days or for 100 consecutive days. The Gehan–Breslow–Wilcoxon P values are indicated.